XML 35 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements:
Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):
  Fair Value Measurements at Reporting Date Using
As of December 31, 2020Fair ValueQuoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Valuation Technique (1)
Other long-term assets:     
Equity securities$72.6 $— $72.6 $— M
Debt securities— — — — M
Redeemable noncontrolling interests31.6 — — 31.6 I
As of December 31, 2019     
Other long-term assets:     
Equity securities$63.5 $— $63.5 $— M
Debt securities12.6 12.6 — — M
Redeemable noncontrolling interests239.6 — — 239.6 I
(1)The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).
The decrease in Redeemable noncontrolling interests from December 31, 2019 to December 31, 2020 primarily resulted from the final purchase of equity interests in Holdings from management investors discussed in Note 12, Redeemable Noncontrolling Interests.
In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets.
As a result of our consolidation of the Jupiter, Florida home health agency and the remeasurement of our previously held equity interest at fair value, we recorded a $2.2 million gain as part of Other income during the year ended December 31, 2020. Also, as a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2 million gain as part of Other income during the year ended December 31, 2019. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's or agency’s projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital or agency. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. See Note 9, Investments in and Advances to Nonconsolidated Affiliates for additional information. During the year ended December 31, 2018, we did not record any material gains or losses related to assets not required to be measured at fair value on a recurring basis.
As discussed in Note 1, Summary of Significant Accounting Policies, “Fair Value Measurements,” the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):
 As of December 31, 2020As of December 31, 2019
 Carrying AmountEstimated Fair ValueCarrying AmountEstimated Fair Value
Long-term debt:    
Advances under revolving credit facility$— $— $45.0 $45.0 
Term loan facilities251.6 253.1 265.2 266.6 
5.125% Senior Notes due 2023
298.1 302.6 297.3 306.6 
5.75% Senior Notes due 2024
— — 697.3 708.8 
5.75% Senior Notes due 2025
346.3 361.4 345.6 369.7 
4.50% Senior Notes due 2028
785.0 840.0 491.7 519.4 
4.75% Senior Notes due 2030
783.2 856.0 491.7 520.0 
4.625% Senior Notes due 2031
393.2 424.9 — — 
Other notes payable39.8 39.8 44.7 44.7 
Financial commitments:    
Letters of credit— 36.7 — 38.9 
Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies, “Fair Value Measurements” and “Redeemable Noncontrolling Interests.”